• Je něco špatně v tomto záznamu ?

Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis

K. Farkas, M. Rutka, PA. Golovics, Z. Végh, BD. Lovász, T. Nyári, KB. Gecse, M. Kolar, M. Bortlik, D. Duricova, N. Machkova, V. Hruba, M. Lukas, K. Mitrova, K. Malickova, A. Bálint, F. Nagy, R. Bor, Á. Milassin, Z. Szepes, K. Palatka, PL....

. 2016 ; 10 (11) : 1273-1278. [pub] 20160421

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023574

INTRODUCTION: CT-P13 is the first biosimilar to infliximab that has been approved for the same indications as its originator infliximab. No data are available on the effect of infliximab biosimilar on mucosal healing. The aim of this study was to evaluate the efficacy of CT-P13 induction therapy on mucosal healing in patients with ulcerative colitis [UC]. PATIENTS AND METHODS: UC patients, who received CT-P13 therapy from its local introduction at three Hungarian and one Czech inflammatory bowel disease centres, were prospectively enrolled. Sigmoidoscopy was performed after the end of the induction therapy at week 14. Mucosal healing was defined as Mayo endoscopic subscore 0 or 1. Complete mucosal healing was defined as Mayo endoscopic subscore 0. Trough level of CT-P13 was measured at week 14. RESULTS: Sixty-three UC patients who underwent CT-P13 induction therapy were enrolled in the study. Indication for the therapy was acute, severe flare up and chronic, refractory activity in 24 and 39 patients, respectively. Cumulative clinical response and steroid-free remission at week 14 were achieved in 82.5% and 47.6% of the patients, respectively. Sigmoidoscopy revealed steroid-free mucosal healing in 47.6% of the patients, and complete mucosal healing was present in 27%. Mayo endoscopic subscore decreased significantly at week 14 compared to baseline. Trough levels of infliximab correlated with mucosal healing. CONCLUSION: This is, to our knowledge, the first study examining the efficacy of CT-P13 induction therapy on mucosal healing in UC. The results indicate that mucosal healing is achieved in two-thirds of UC patients by the end of the induction treatment with CT-P13.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023574
003      
CZ-PrNML
005      
20170906121520.0
007      
ta
008      
170720s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ecco-jcc/jjw085 $2 doi
035    __
$a (PubMed)27106537
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Farkas, Klaudia $u 1 Department of Medicine, University of Szeged, Szeged, Hungary.
245    10
$a Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis / $c K. Farkas, M. Rutka, PA. Golovics, Z. Végh, BD. Lovász, T. Nyári, KB. Gecse, M. Kolar, M. Bortlik, D. Duricova, N. Machkova, V. Hruba, M. Lukas, K. Mitrova, K. Malickova, A. Bálint, F. Nagy, R. Bor, Á. Milassin, Z. Szepes, K. Palatka, PL. Lakatos, M. Lukas, T. Molnár,
520    9_
$a INTRODUCTION: CT-P13 is the first biosimilar to infliximab that has been approved for the same indications as its originator infliximab. No data are available on the effect of infliximab biosimilar on mucosal healing. The aim of this study was to evaluate the efficacy of CT-P13 induction therapy on mucosal healing in patients with ulcerative colitis [UC]. PATIENTS AND METHODS: UC patients, who received CT-P13 therapy from its local introduction at three Hungarian and one Czech inflammatory bowel disease centres, were prospectively enrolled. Sigmoidoscopy was performed after the end of the induction therapy at week 14. Mucosal healing was defined as Mayo endoscopic subscore 0 or 1. Complete mucosal healing was defined as Mayo endoscopic subscore 0. Trough level of CT-P13 was measured at week 14. RESULTS: Sixty-three UC patients who underwent CT-P13 induction therapy were enrolled in the study. Indication for the therapy was acute, severe flare up and chronic, refractory activity in 24 and 39 patients, respectively. Cumulative clinical response and steroid-free remission at week 14 were achieved in 82.5% and 47.6% of the patients, respectively. Sigmoidoscopy revealed steroid-free mucosal healing in 47.6% of the patients, and complete mucosal healing was present in 27%. Mayo endoscopic subscore decreased significantly at week 14 compared to baseline. Trough levels of infliximab correlated with mucosal healing. CONCLUSION: This is, to our knowledge, the first study examining the efficacy of CT-P13 induction therapy on mucosal healing in UC. The results indicate that mucosal healing is achieved in two-thirds of UC patients by the end of the induction treatment with CT-P13.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a monoklonální protilátky $x terapeutické užití $7 D000911
650    _2
$a biosimilární léčivé přípravky $x terapeutické užití $7 D059451
650    _2
$a ulcerózní kolitida $x farmakoterapie $x patologie $7 D003093
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a gastrointestinální látky $x terapeutické užití $7 D005765
650    _2
$a lidé $7 D006801
650    _2
$a infliximab $x terapeutické užití $7 D000069285
650    _2
$a střevní sliznice $x patologie $7 D007413
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Rutka, Mariann $u 1 Department of Medicine, University of Szeged, Szeged, Hungary.
700    1_
$a Golovics, Petra A $u 1 Department of Medicine, Semmelweis University, Budapest, Hungary.
700    1_
$a Végh, Zsuzsanna $u 1 Department of Medicine, Semmelweis University, Budapest, Hungary.
700    1_
$a Lovász, Barbara D $u 1 Department of Medicine, Semmelweis University, Budapest, Hungary.
700    1_
$a Nyári, Tibor $u Department of Medical Physics and Informatics, University of Szeged, Szeged, Hungary.
700    1_
$a Gecse, Krisztina B $u 1 Department of Medicine, Semmelweis University, Budapest, Hungary.
700    1_
$a Kolar, Martin $u IBD Clinical and Research Centre, Iscare a.s., Prague, Czech Republic. 1 Medical Faculty, Charles University, Prague, Czech Republic.
700    1_
$a Bortlik, Martin $u IBD Clinical and Research Centre, Iscare a.s., Prague, Czech Republic. Department of Internal Medicine, Military Hospital, Charles University, Prague, Czech Republic.
700    1_
$a Duricova, Dana $u IBD Clinical and Research Centre, Iscare a.s., Prague, Czech Republic. Institute of Pharmacology, 1 Medical Faculty, Charles University, Prague, Czech Republic.
700    1_
$a Machkova, Nadezda $u IBD Clinical and Research Centre, Iscare a.s., Prague, Czech Republic.
700    1_
$a Hruba, Veronika $u IBD Clinical and Research Centre, Iscare a.s., Prague, Czech Republic.
700    1_
$a Lukas, Martin $u IBD Clinical and Research Centre, Iscare a.s., Prague, Czech Republic.
700    1_
$a Mitrova, Katarina $u IBD Clinical and Research Centre, Iscare a.s., Prague, Czech Republic. Department of Paediatrics, Faculty Hospital Motol, 2 Medical Faculty, Charles University, Prague, Czech Republic.
700    1_
$a Malickova, Karin $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1 Medical Faculty and General Teaching Hospital, Charles University, Prague, Czech Republic.
700    1_
$a Bálint, Anita $u 1 Department of Medicine, University of Szeged, Szeged, Hungary.
700    1_
$a Nagy, Ferenc $u 1 Department of Medicine, University of Szeged, Szeged, Hungary.
700    1_
$a Bor, Renáta $u 1 Department of Medicine, University of Szeged, Szeged, Hungary.
700    1_
$a Milassin, Ágnes $u 1 Department of Medicine, University of Szeged, Szeged, Hungary.
700    1_
$a Szepes, Zoltán $u 1 Department of Medicine, University of Szeged, Szeged, Hungary.
700    1_
$a Palatka, Károly $u 2 Department of Medicine, University of Debrecen, Debrecen, Hungary.
700    1_
$a Lakatos, Péter L $u 1 Department of Medicine, Semmelweis University, Budapest, Hungary.
700    1_
$a Lukas, Milan $u IBD Clinical and Research Centre, Iscare a.s., Prague, Czech Republic. Institute of Medical Biochemistry and Laboratory Diagnostics, 1 Medical Faculty and General Teaching Hospital, Charles University, Prague, Czech Republic.
700    1_
$a Molnár, Tamás $u 1 Department of Medicine, University of Szeged, Szeged, Hungary molnar.tamas@med.u-szeged.hu.
773    0_
$w MED00166945 $t Journal of Crohn's & colitis $x 1876-4479 $g Roč. 10, č. 11 (2016), s. 1273-1278
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27106537 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170906122118 $b ABA008
999    __
$a ok $b bmc $g 1239255 $s 984487
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 10 $c 11 $d 1273-1278 $e 20160421 $i 1876-4479 $m Journal of Crohn's and colitis $n J Crohns Colitis $x MED00166945
LZP    __
$a Pubmed-20170720
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace